Answers are grounded in this paper and cite their sources.
Myositis-myocarditis-myasthenia gravis (MMM) overlap syndrome is a rare, potentially fatal complication of immune checkpoint inhibitor (ICI) therapy. We report a 74-year-old man with pre-existing thymoma and anti-acetylcholine receptor antibody positivity who developed pembrolizumab-induced MMM complicated by gastrointestinal pseudo-obstruction (GIPO). Despite the administration of corticosteroids and intravenous immunoglobulin, ocular symptoms persisted, and bowel dysmotility progressed. We initiated zilucoplan, a complement C5 inhibitor. Within days, diplopia and dysphagia resolved, and GIPO markedly improved on radiography, enabling oral intake. To our knowledge, this is the first case of pembrolizumab-induced MMM treated with zilucoplan and the first ICI-mediated GIPO managed with a complement inhibitor.
No takes yet. Share an insight, caveat, or question.
Komatsu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: